Sapacitabine

Drug Profile

Sapacitabine

Alternative Names: CS-682; CYC-682

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company; Hokkaido University; Kanazawa University
  • Developer Cyclacel Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Arabinonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Chronic lymphocytic leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Preclinical Ovarian cancer
  • Discontinued Cutaneous T cell lymphoma

Most Recent Events

  • 03 Dec 2016 Leukaemia and Lymphoma Research Institute and National Cancer Research Institute terminates the AML-LI-1 trial in Acute myeloid leukaemia (Combination therapy, First line therapy) in United Kingdom and Denmark
  • 06 Jun 2016 Efficacy, adverse events and pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
  • 29 Mar 2016 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in USA (PO), prior to March 2016 (Cyclacel Pharmaceuticals 10-K; March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top